The prevalence of Allergic Rhinitis in OSA/SDB is considerably high and children with SDB suffering from a higher incidence of AR than non-SDB. OSA adults accompanied with AR do not have any influences on sleep parameters.
Allergic rhinitis (AR); obstructive sleep apnea (OSA); sleep-disordered breathing (SDB).
Risk factors in relation to allergic rhinitis (AR) remain unclear despite considerable interest. This study aimed to analysis the relationship between home environment and diseases in early life and AR.
After 2-week treatment period, bilastine 20 mg once daily was effective and tolerable in Japanese patients with perennial allergic rhinitis (PAR), and exhibited a rapid onset of action.
Bilastine 10 mg had a safety and tolerability profile similar to that of placebo in children aged 2 to <12 years with allergic rhinoconjunctivitis or chronic urticaria.
Based on its pharmacokinetic properties, efficacy, and tolerability profile, bilastine will be valuable in the management of allergic rhinitis and urticaria.
Chronic idiopathic urticaria (CIU) is a debilitating skin condition that can profoundly affect patients’ quality of life. This study explored the impact of refractory and nonrefractory CIU on patients in the real-world setting in the United States.
Background: Allergic diseases are on the rise in many parts of the world, including the Asia–Pacifc (APAC) region.
Second-generation antihistamines are the frst-line treatment option in the management of allergic rhinitis and urticaria. International guidelines describe the management of these conditions; however, clinicians perceive the additional need to tailor treatment according to patient profles. This study serves as a consensus of experts from several countries in APAC (Hong Kong, Malaysia, the Philippines, Singapore, Thailand, Vietnam), which aims to describe the unmet needs, practical considerations, challenges, and key decision factors when determining optimal secondgeneration antihistamines for patients with allergic rhinitis and/or urticaria.
Methods: Specialists from allergology, dermatology, and otorhinolaryngology were surveyed on practical considerations and key decision points when treating patients with allergic rhinitis and/or urticaria.
Results: Clinicians felt the need for additional tools for diagnosis of these diseases and a single drug with all preferred features of an antihistamine. Challenges in treatment include lack of clinician and patient awareness and compliance, fnancial constraints, and treatment for special patient populations such as those with concomitant disease. Selection of optimal second-generation antihistamines depends on many factors, particularly drug safety and efcacy, impact on psychomotor abilities, and sedation. Country-specifc considerations include drug availability and cost-efectiveness. Survey results reveal bilastine as a preferred choice due to its high efcacy and safety, suitability for special patient populations, and the lack of sedative efects.
Conclusions: Compliance to the international guidelines is present among allergists, dermatologists and otorhinolaryngologists; however, this is lower amongst general practitioners (GPs). To increase awareness, allergy education programs targeted at GPs and patients may be benefcial. Updates to the existing international guidelines are suggested in APAC to refect appropriate management for diferent patient profles and varying symptoms of allergic rhinitis and urticaria.
Keywords: Allergic rhinitis, Antihistamines, Bilastine, Treatment algorithm, Urticaria.
Bilastine is a new second generation H1‐antihistamine approved for the symptomatic treatment of allergic rhinitis (AR) and chronic urticaria (CU) in patients older than 12 years of age. AR and urticaria are very common clinical conditions that represent one of the most frequent reasons for a patient to visit their general practitioner or allergist or dermatologist. Bilastine, with its efficacy and safety profile epitomizes the evolution of research on antihistamines.
PURPOSE OF REVIEW: Chronic urticaria is a common dermatological condition that has significant impact on quality of life. Multiple international societies have published guidelines, and although these guidelines generally agree on the definition of urticaria, as well as approach to diagnosis and management, there have been notable differences to date. These differences have been reconciled by the recent publication of the 2017 revision and update published by the EAACI/GA2LEN/EDF/WAO.
RECENT FINDINGS: The 2017 revision and update to the guidelines for chronic urticaria are the most comprehensive consensus document to date, and reconcile previously existing differences between the US, European, and Asian guidelines. The purpose of our review is to present basic background on urticaria and discuss classification, diagnosis, and most importantly, management. We present differences from previous US, European, and Asian guidelines and reconcile the previous differences by summarizing the 2017 revision and update published by the EAACI/GA2LEN/EDF/WAO.
© 2024 Bilastina.
La información que está a punto de visualizar está dirigida únicamente a los profesionales sanitarios aptos para prescribir o dispensar medicamentos. La correcta utilización de su contenido requiere de formación como profesional sanitario.
Debe hacer clic en Aceptar para confirmar que es usted profesional de la salud y continuar con la navegación.
ACEPTAR
